Arcutis Biotherapeutics Inc (ARQT)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arcutis Biotherapeutics Inc chart...

About the Company

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Exchange

NASDAQ

Website

arcutis.com

$M

Total Revenue

269

Employees

$991M

Market Capitalization

-2.47

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ARQT News

Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

15h ago, source: Zacks.com on MSN

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $10.66, gaining 14.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

18d ago, source: Hosted on MSN

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript February 27, 2024 Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS ...

Arcutis Biotherapeutics Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

18d ago, source: Yahoo Finance

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) investors will be delighted, with the company turning in some strong numbers with its latest results. Arcutis Biotherapeutics beat expectations with ...

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

7d ago, source:

Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ ...

Arcutis Announces Pricing of $150 Million Public Offering

19d ago, source: Nasdaq

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations ...

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript

20d ago, source: Seeking Alpha

Good day and welcome to the Arcutis Biotherapeutics' 2023 Fourth Quarter and Full Year Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

Arcutis Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […] ...

Q4 2023 Arcutis Biotherapeutics Inc Earnings Call

20d ago, source: Yahoo Finance

Vikram Purohit; Analyst; Morgan Stanley. Sean Kim; Analyst; JonesTrading Operator Good day and welcome to the Arcutis Biotherapeutics 2023 Fourth Quarter and Full Year financial results conference ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...